Sivik Global Healthcare LLC Sells 15,000 Shares of Repligen Co. (NASDAQ:RGEN)

Sivik Global Healthcare LLC decreased its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 60.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,000 shares of the biotechnology company's stock after selling 15,000 shares during the quarter. Sivik Global Healthcare LLC's holdings in Repligen were worth $1,439,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Bank of Montreal Can lifted its stake in shares of Repligen by 4.5% in the 2nd quarter. Bank of Montreal Can now owns 36,752 shares of the biotechnology company's stock worth $4,641,000 after purchasing an additional 1,575 shares during the period. Cubist Systematic Strategies LLC increased its holdings in Repligen by 623.0% during the second quarter. Cubist Systematic Strategies LLC now owns 6,196 shares of the biotechnology company's stock valued at $781,000 after buying an additional 5,339 shares during the last quarter. MBB Public Markets I LLC bought a new position in Repligen in the second quarter worth approximately $492,000. The Manufacturers Life Insurance Company boosted its stake in shares of Repligen by 4.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 67,701 shares of the biotechnology company's stock worth $8,534,000 after acquiring an additional 2,946 shares during the last quarter. Finally, Dana Investment Advisors Inc. grew its position in shares of Repligen by 45.7% during the 2nd quarter. Dana Investment Advisors Inc. now owns 6,071 shares of the biotechnology company's stock valued at $765,000 after acquiring an additional 1,903 shares during the period. Institutional investors own 97.64% of the company's stock.

Repligen Price Performance

Repligen stock traded down $1.32 during mid-day trading on Friday, reaching $166.21. 340,049 shares of the company's stock traded hands, compared to its average volume of 581,997. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a market cap of $9.31 billion, a price-to-earnings ratio of -449.20, a PEG ratio of 4.76 and a beta of 0.97. The stock has a 50 day moving average of $154.24 and a two-hundred day moving average of $147.64. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same period last year, the company earned $0.23 earnings per share. Repligen's revenue was up 9.7% on a year-over-year basis. Equities analysts forecast that Repligen Co. will post 1.54 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on RGEN. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price on the stock. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Friday, January 3rd. Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price for the company. HC Wainwright lowered their price target on shares of Repligen from $240.00 to $180.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. Finally, Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Repligen currently has a consensus rating of "Moderate Buy" and an average target price of $184.73.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.